STUDY
DESIGN

Adults with anti-AChR Ab+ and anti-MuSK Ab+ gMG participated in the RYSTIGGO Phase 3 MycarinG clinical trial and in two extension studies1,2

REVIEW STUDY DESIGN

Adults with anti-AChR Ab+ and anti-MuSK Ab+ gMG participated in the RYSTIGGO Phase 3 MycarinG clinical trial and in two extension studies1,2

MycarinG CLINICAL TRIAL

RYSTIGGO was evaluated in a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of adults with mild-to-severe gMG1,2

The efficacy and safety of RYSTIGGO for the treatment of gMG were established in an 18-week, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. In the study, 200 adults with gMG at least 18 years of age were randomized 1:1:1 to receive weight-tiered doses of RYSTIGGO (n=133), either 7 mg/kg of RYSTIGGO (n=66) or 10 mg/kg of RYSTIGGO (n=67), or placebo (n=67). All patients continued on current therapies.1,2

RYSTIGGO® Clinical Trial Design.
RYSTIGGO® Clinical Trial Design.

Inclusion criteria1,2

Adults enrolled in the study met the following criteria:

  • Presence of autoantibodies against AChR or MuSK
  • MGFA Clinical Classification Class II to IVa
  • MG-ADL total score of at least 3 (with ≥3 points from non-ocular symptoms)
  • On stable dose of MG therapy prior to screening that included AChE inhibitors, steroids, or other NSISTs, either in combination or alone
  • Serum IgG levels of at least 5.5 g/L
  • QMG score of at least 11

Baseline characteristics2,3

 
RYSTIGGO 7 mg/kg (n=66)
RYSTIGGO 10 mg/kg (n=67)
Placebo (n=67)
Mean age in years
53
52
50
Median duration of disease in years
5.3
5.7
6.8
Gender distribution, % female
59%
52%
70%
Race, % White
62%
73%
69%
Race, % Asian
14%
10%
7%
Race, % Black
0%
6%
1%
Race, % American Indian or Alaska Native
0%
0%
0%
Ethnicity, % Hispanic or Latino
8%
5%
8%
Mean MG-ADL score at baseline
8.4
8.1
8.4
Mean QMG score at baseline
15.4
15.6
15.8
Anti-AChR Ab+, n (%)
60 (91%)*
60 (90%)
59 (88%)*
Anti-MuSK Ab+, n (%)
5 (8%)
8 (12%)†
8 (12%)†
MGFA Class IIa, n (%)
13 (20%)
13 (19%)
11 (16%)
MGFA Class IIb, n (%)
16 (24%)
13 (19%)
12 (18%)
MGFA Class IIIa, n (%)
21 (32%)
26 (39%)
28 (42%)
MGFA Class IIIb, n (%)
13 (20%)
13 (19%)
13 (19%)
MGFA Class IVa, n (%)
3 (5%)
2 (3%)
2 (3%)
MGFA Class IVb, n (%)
0 (0%)
0 (0%)
1 (1%)‡
Treatment with acetylcholinesterase inhibitors, n (%)
55 (83%)
57 (85%)
60 (90%)
Treatment with corticosteroids, n (%)
43 (65%)
48 (72%)
38 (57%)
Treatment with non-steroidal immunosuppressive therapies (NSISTs), n (%)
32 (48%)
38 (57%)
33 (49%)

Includes one patient who had unknown AChR and MuSK autoantibody status.2

Includes one patient who had positive AChR and MuSK autoantibody status.2

Patient was classified as MGFA class III at screening, but class IVb at baseline.2

EXTENSION STUDIES

The long-term safety and efficacy of RYSTIGGO was evaluated in adults in two extension studies3

Adults from MycarinG could enroll in two extension studies, MG0004 and MG0007, that further evaluated the safety and efficacy of RYSTIGGO over time.3

MG0004 (NCT04124965)

MG0004 was an up to 60-week, multicenter, randomized, Phase 3 extension study. 71 adults from MycarinG who met eligibility criteria were randomized to receive either RYSTIGGO 7 mg/kg or 10 mg/kg. Patients received RYSTIGGO once weekly for a period of up to 52 weeks, followed by 8 weeks of observation. MG0004 enrollment was closed upon the initiation of study MG0007.3

MG0007 (NCT04650854)

MG0007 was a multicenter Phase 3 study that included 165 adults from MycarinG and MG0004. It assessed the long-term safety and efficacy of RYSTIGGO given in repeated 6-week cycles, based on the manifestation of gMG symptoms.3,4

Graphic describing two extension studies (MG0004 and MG0007) that were available to adults who participated in the MycarinG clinical trial to further evaluate the safety and efficacy of RYSTIGGO®.
Graphic describing two extension studies (MG0004 and MG0007) that were available to adults who participated in the MycarinG clinical trial to further evaluate the safety and efficacy of RYSTIGGO®.

Ab+=antibody positive; AChE=acetylcholinesterase; AChR=acetylcholine receptor; gMG=generalized myasthenia gravis; IgG=immunoglobulin G; MG=myasthenia gravis; MG-ADL=Myasthenia Gravis Activities of Daily Living; MGFA=Myasthenia Gravis Foundation of America; MuSK=muscle-specific tyrosine kinase; NSISTs=non-steroidal immunosuppressive therapies; SQ=subcutaneous; QMG=Quantitative Myasthenia Gravis.

References:

  1. RYSTIGGO [Prescribing Information]. Smyrna, GA: UCB, Inc.
  2. Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383-394. doi:10.1016/S1474-4422(23)00077-7
  3. Bril V, Drużdż A, Grosskreutz J, et al. Rozanolixizumab in generalized myasthenia gravis: pooled analysis of the phase 3 MycarinG study and two open-label extensions. J Neuromuscul Dis. 2025;12(2):218-230. doi:10.1177/22143602241305511
  4. Data on file. UCB, Inc., Smyrna, GA.

UP NEXT

DOSING